Loading...
•
Mar 31, 2023
MacroGenics Q1 2023 Earnings Report
MacroGenics reported first quarter 2023 financial results and provided a corporate progress update.
Key Takeaways
MacroGenics reported a net loss of $38.0 million for the quarter ended March 31, 2023, compared to a net loss of $66.4 million for the quarter ended March 31, 2022. Total revenue was $24.5 million, compared to $11.1 million for the quarter ended March 31, 2022. The company's cash, cash equivalents and marketable securities were $241.7 million as of March 31, 2023, and anticipates its cash runway through 2025.
ZYNYZ™ is the third product approved in the U.S. that originated from MacroGenics' pipeline.
Multiple Phase 2 programs are advancing in metastatic castration-resistant prostate cancer (mCRPC).
The company achieved $270 million in non-dilutive funding over the past nine months.
Cash runway extends through 2025.
Revenue by Segment
Forward Guidance
MacroGenics anticipates that its cash, cash equivalents and marketable securities balance of $241.7 million as of March 31, 2023, plus projected and anticipated future payments from partners and product revenues should extend its cash runway through 2025.
Revenue & Expenses
Visualization of income flow from segment revenue to net income
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...